Document is current
Any future updates will be listed below
-
Authors
Freyer, Oscar
Wrona, Kamil J.
de Snoeck, Quentin
Hofmann, Moritz
Melvin, Tom
Stratton-Powell, Ashley
Wicks, Paul
Parks, Acacia C.
Gilbert, Stephen
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (16KISA100K)
Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen
Technische Universität Dresden
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 30 August 2024
First Online: 9 September 2024
Competing interests
: P.W. is employed by Wicks Digital Health Ltd, which has received funding from Ada Health, AstraZeneca, Biogen, Bold Health, Corevitas, EIT, Endava, Happify, HealthUnlocked, Inbeeo, Kheiron Medical, Lindus Health, MedRhythms, Okko Health, PatientsLikeMe, Sano Genetics, The Learning Corp, The Wellcome Trust, THREAD Research, Unite Genomics, VeraSci, and Woebot Health. P.W. and spouse are shareholders of WDH Investments, Ltd., which owns stock in Avayl Gmbh, BlueSkeye AI Ltd, Earswitch Ltd, Lucida Medical Ltd, RunYourself Ltd, Sano Genetics Ltd, and Una Health GmbH. S.G. declares a nonfinancial interest as an Advisory Group member of the EY-coordinated “Study on Regulatory Governance and Innovation in the field of Medical Devices” conducted on behalf of the DG SANTE of the European Commission. S.G. declares the following competing financial interests: he has or has had consulting relationships with Una Health GmbH, Lindus Health Ltd., Flo Ltd, Thymia Ltd., FORUM Institut für Management GmbH, High-Tech Gründerfonds Management GmbH, and Ada Health GmbH and holds share options in Ada Health GmbH. A.S-P. is a Principal Regulatory Consultant for RQM + but does not have competing interests associated with this research. O.F., K.J.W., Q.S., M.H., T.M., and A.P. declare no competing interest with this research.
